OBJECTIVE: This study examined the association between cardiac function and pulmonary function in hypertensive patients. METHODS: Hypertensive patients without overt cardiovascular disease were enrolled (n = 43; mean ± SD age 71 ± 9 years). Pulmonary function was measured by the percentage of predicted forced vital capacity (%FVC) and the ratio of 1 s forced expiratory volume (FEV 1 ) to FVC (FEV 1 /FVC ratio). Left ventricular ejection fraction (LVEF) and the ratio of peak early diastolic transmitral flow (E) to peak early diastolic mitral annular velocity (e′) (E/e′ ratio) were assessed using echocardiography. RESULTS:
Introduction
Current heart failure guidelines indicate that asymptomatic cardiac dysfunction is an important stage preceding progression to clinically overt heart failure. 1 Heart failure syndrome involves multiple organ systems and even mild functional derangement of a noncardiac organ system may accelerate the manifestation of overt heart failure, particularly when other organ systems are also involved. 2 Emerging evidence suggests that subclinical renal impairment, 3 hypoalbuminaemia, 4 decline of pulmonary function, 5, 6 anaemia 7 and systemic inflammation 8 may contribute to heart failure progression. Magnetic resonance imaging studies have revealed an association between cardiac dysfunction and H Masugata, S Senda, H Okada et al. Cardiac and pulmonary function in hypertension chronic obstructive pulmonary disease (COPD) in community-dwelling adults. 5, 6, 9 There are no data, however, regarding cardiac and pulmonary function in hypertensive patients.
It is recognized that COPD is a systemic disease, 10 and the association between COPD and cardiovascular disease has received attention. 11, 12 Several studies have demonstrated associations between COPD and abnormalities of systemic vascular dysfunction 13, 14 which may lead to progression of hypertension. We have hypothesized that vascular dysfunction may lead to increased arterial stiffness, producing cardiac dysfunction in hypertension by increasing the afterload of the left ventricle. The present study examined the relationships between cardiac function, as assessed by echocardiography, and pulmonary function in hypertensive patients.
Patients and methods

STUDY POPULATION
Outpatients previously diagnosed with hypertension who were attending the Department of Integrated Medicine of Kagawa University Hospital (Kagawa, Japan) for routine monitoring between September 2010 and March 2011 were recruited to the study. Participants were required to have been taking antihypertensive medications for at least 1 year. Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, based on blood pressure data obtained at least 1 year prior to study entry. Exclusion criteria were: (i) current haemodialysis; (ii) history of heart failure or ischaemic heart disease; (iii) serum creatinine > 2.0 mg/dl; and (iv) history of atherosclerotic cardiovascular disease or stroke.
The smoking status of participants was defined as: 'current smokers', those who smoked at least one cigarette per day during the month before enrolment; 'former smokers', those who smoked at least one cigarette per day at any time prior to the month before enrolment; and 'never smokers', those who had never smoked.
The study protocol was approved by the Ethics Committee of Kagawa University (Kagawa, Japan). Written informed consent was obtained from all participants.
LABORATORY DATA
Blood samples were taken in the morning after a 12 h overnight fast. Blood was collected in tubes containing ethylenediaminetetra-acetic acid or heparin and was analysed immediately. Plasma total cholesterol, triglyceride, high-density lipoprotein cholesterol, creatinine, high-sensitivity Creactive protein (hsCRP), haemoglobin levels and white blood cell counts were measured by standard laboratory techniques.
ECHOCARDIOGRAPHIC EXAMINATION
Two-dimensional and M-mode echocardiographies were performed using the Vivid 7 system (GE Healthcare, Horten, Norway). The following left ventricular (LV) structural parameters were measured by M-mode echocardiography: ventricular septal thickness (VS) at the chordae tendineae level; LV enddiastolic dimension (LVDd) and LV endsystolic dimension at the chordae tendineae level; and LV posterior wall (PW) thickness at the chordae tendineae level. The LV mass was calculated according to the American Society of Echocardiography convention, using the following formula: LV mass = 0.80 (1.04 × [PW + VS + LVDd] 3 -[LVDd] 3 ) + 0.6. 15 The LV mass index (LVMI) was calculated as LV mass divided by body surface area and was used as H Masugata, S Senda, H Okada et al.
Cardiac and pulmonary function in hypertension
a parameter of LV hypertrophy. The LV ejection fraction (LVEF) was estimated by Teichholz's method and was used as the parameter of LV systolic function. 16 The LV diastolic function parameters were measured by recording transmitral flow velocity using conventional Doppler echocardiography. 17 Transmitral flow velocity was recorded from the apical transducer position with the sample volume situated between the mitral leaflet tips. The peak velocity of early transmitral flow velocity (E) and the peak velocity of late transmitral flow velocity (A) were recorded, and the E/A ratio was calculated. The deceleration time of E (DcT) was measured as the time interval from the E-wave peak to the decline of velocity to baseline.
Pulsed-wave tissue Doppler echocardiography was also performed as a measure of LV diastolic function. Mitral annular velocities were recorded from the apical window. Sample volumes were located at the septal site of the mitral annulus. The mean of three peak early diastolic mitral annular velocity (e′) measurements was recorded. 18, 19 The ratio of E/e′ was calculated and used as a parameter of LV preload. 20
PULMONARY FUNCTION TESTS
Blood pressure was determined using the conventional cuff method prior to pulmonary function testing, after a 5 min rest in a sitting position.
Pulmonary function tests were performed using a computed spirometer (DISCOM-21FX; Chest MI Inc., Tokyo, Japan). Forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV 1 ) from the best tests, as defined by the American Thoracic Society, 21 were recorded. Published equations 21 were used to calculate predicted FVC for each patient. The percentage of predicted FVC (%FVC) was calculated as a parameter of restrictive ventilatory defects. The FEV 1 /FVC ratio was calculated as a parameter of obstructive ventilatory defects.
STATISTICAL ANALYSES
The mean ± SD values of the data were calculated and statistical analyses were performed using the SPSS ® statistical package, version 18.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Simple linear regression analysis was performed to evaluate the association between parameters of the pulmonary function test, echocardiographic parameters and other variables. Stepwise multiple regression analysis was performed to identify independent predictors of the pulmonary function parameters. Comparisons were made between hypertensive never smokers and hypertensive former/current smokers using the unpaired ttest for continuous variables and the χ 2 -test for categorical data. A value of P < 0.05 was considered statistically significant.
Results
The study recruited 43 hypertensive patients (22 males, 21 females; mean ± SD age 71 ± 9 years; age range 50 -84 years). Their demographic, clinical, echocardiographic and pulmonary function parameters are summarized in Table 1 . Mean systolic and diastolic blood pressures were not hypertensive because the blood pressure of the participants was well controlled.
Simple linear regression analysis revealed significant correlations between FVC and age (P = 0.018), former smoker status (P = 0.022), never smoker status (P = 0.017), haemoglobin (P = 0.022), creatinine (P = 0.016), A (P = 0.002), e′ (P = 0.018) and E/e′ (P < 0.001; Table 2 ). Stepwise multiple regression analysis indicated that only E/e′ was independently significantly associated with FVC (P = 0.001; Table 2 ).
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Simple linear regression analysis also revealed a significant correlation between %FVC and hsCRP (P = 0.017), DcT (P = 0.009) and E/e′ (P = 0.022; Table 2 ). Stepwise multiple regression analysis indicated that only E/e′ was independently associated with the %FVC (P = 0.012; Table 2 ).
Simple linear regression analysis indicated that FEV 1 was significantly correlated with age (P = 0.001), A (P = 0.007), e′ (P = 0.011) and E/e′ (P = 0.001; Table 2 ).
Stepwise multiple regression analysis indicated that only E/e′ was independently associated with FEV 1 (P = 0.001).
The FEV 1 /FVC ratio was significantly correlated with age (P = 0.028), former smoker status (P = 0.002), never smoker status (P = 0.019) and LVEF (P = 0.005) by simple linear regression analysis ( Table 2) . Stepwise multiple regression analysis indicated that only LVEF was independently associated with the FEV 1 /FVC ratio (P = 0.001; Table 2 ).
Clinical echocardiographic and pulmonary function parameters were compared between hypertensive never smokers and former/current smokers (Table 3 ). LVEF and the FEV 1 /FVC ratio were both significantly lower in hypertensive former/current smokers than in hypertensive never smokers (P = 0.003 and P = 0.019, respectively).
Discussion
This study investigated the relationship between cardiac and pulmonary function in hypertensive patients who had been receiving antihypertensive treatment for at least 1 year. LV hypertrophy (as assessed by LVMI) was not associated with decreased pulmonary function. LV diastolic dysfunction (as assessed by E/e′) was associated with decreased FVC, and LV systolic dysfunction (as assessed by LVEF) was associated with decreased FEV 1 /FVC ratio. In addition, hypertensive former/ (P < 0.001) (P = 0.001) (P = 0.022) (P = 0.012) (P = 0.001) (P = 0.001) BMI, body mass index; ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; HDL, highdensity lipoprotein; hsCRP, high-sensitivity C-reactive protein; LVMI, left ventricular mass index; LVEF, left ventricular ejection fraction; E, peak early diastolic transmitral flow velocity; A, peak late diastolic transmitral flow velocity; DcT, deceleration time of E; e′, peak early diastolic mitral annular velocity;
NS, not statistically significant (P > 0.05).
TABLE 2 (continued): Results of simple linear and stepwise multiple regression analyses on various clinical and echocardiographic parameters for forced vital capacity (FVC), percentage of predicted FVC (%FVC), forced expiratory volume in 1 s (FEV
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current smokers showed a reduction in both cardiac and pulmonary functions compared with hypertensive never smokers.
Aging is known to influence both cardiac and pulmonary function. 2, 5 The present study found that FVC, FEV 1 and the FEV 1 /FVC ratio were correlated with age in simple linear regression analysis. Multiple linear 
regression analysis indicated that the cardiac function parameters E/e′ and LVEF were independently associated with the pulmonary function parameters %FVC and FEV 1 /FVC, respectively. These findings indicate that mechanisms other than aging contributed to the association between cardiac and pulmonary functions in the hypertensive patients in the present study.
Previous studies have demonstrated an association between cardiac dysfunction and COPD in community-dwelling adults. 5, 6, 9 This is in accord with the results of the present study which revealed an association between cardiac and pulmonary functions in hypertensive patients. It is well known that LV hypertrophy is an established marker of cardiovascular events, including heart failure, in patients with essential hypertension. 22, 23 In the present study, LV hypertrophy (as assessed by LVMI) was not associated with pulmonary function, but LV function was. This may be due to the fact that the blood pressure of the study participants was well controlled and LV hypertrophy was not apparent in the present study (normal LVMI ≤ 115 g/m 2 for men and ≤ 95 g/m 2 for women). 24 Cardiac damage due to hypertension may, therefore, have been mild in these patients. These data suggest that LV dysfunction may be more sensitive than LV hypertrophy as a predictor of decreased pulmonary function. Studies have demonstrated that increased arterial stiffness is associated with pulmonary function in COPD patients. 13, 14 This increased arterial stiffness results in increased afterload of the left ventricle and is likely to lead to LV hypertrophy. Further studies including patients with more severe hypertension and LV hypertrophy are needed to elucidate the association between LV hypertrophy and pulmonary function.
It is recognized that COPD is a systemic disease, 10 and the association between COPD and cardiovascular disease has received attention. 12 COPD is caused by obstructive ventilatory defects which can be diagnosed by spirometry. In the present study, LVEF was independently associated with FEV 1 /FVC, indicating obstructive ventilatory defects. These data suggest that hypertensive patients with COPD may have subclinically decreased LVEF and are at a high risk of heart failure. The link between increased cardiovascular disease and COPD is believed to be mediated by persistent low-grade systemic inflammation, as indicated by elevated levels of CRP observed in patients with COPD. 25 Increased CRP levels are associated with raised cardiovascular risk in the general population and poor prognosis in patients with COPD. 26, 27 CRP plays a causal role in atherosclerosis, 28 metabolic syndrome, 29 and coronary heart disease and ischaemic heart failure. 30 Previous studies have demonstrated an association between hsCRP and microvascular complications, including nephropathy and retinopathy, in patients with hypertension and diabetes. 31, 32 Since LV dysfunction is also produced by microvascular complications in hypertension and diabetes, 33, 34 LV dysfunction is likely to be associated with increased hsCRP levels. 35 Low-grade systemic inflammation may have led to an association between subclinical cardiac dysfunction and decreased pulmonary function in the present study.
Obstructive ventilatory defects from an inappropriate and excessive inflammatory response of the lungs to respiratory pollutants, mainly tobacco smoking, characterize COPD. 36, 37 In the present study, cardiac and pulmonary functions were compared in hypertensive patients according to smoking status (never smokers or former/current smokers). There was no • Received for publication 27 July 2011 • Accepted subject to revision 2 August 2011
• Revised accepted 5 December 2011 Copyright © 2012 Field House Publishing LLP statistically significant difference in hsCRP concentrations between the two groups, but both LVEF and FEV 1 /FVC were lower in former/current smokers than in never smokers. Hypertensive patients should, in any case, be strongly encouraged to stop smoking to prevent the progression of cardiopulmonary dysfunction.
The present study was limited by the relatively small sample size, resulting in only a few significant correlations between cardiac and pulmonary functions. Larger studies are needed to confirm the statistically significant association between cardiac and pulmonary functions in hypertensive patients.
In conclusion, subclinical cardiac dysfunction was shown to be independently associated with reduced pulmonary function in hypertensive patients, and both cardiac and pulmonary dysfunctions were found to be related to smoking status. Hypertensive patients with decreased pulmonary function may need preventive care to prevent the progression of heart failure.
